Deep-learning-based virtual screening of antibacterial compounds
- PMID: 41136774
- DOI: 10.1038/s41587-025-02814-6
Deep-learning-based virtual screening of antibacterial compounds
Erratum in
-
Publisher Correction: Deep-learning-based virtual screening of antibacterial compounds.Nat Biotechnol. 2025 Nov 7. doi: 10.1038/s41587-025-02941-0. Online ahead of print. Nat Biotechnol. 2025. PMID: 41203993 No abstract available.
Abstract
The increase in multidrug-resistant bacteria underscores an urgent need for additional antibiotics. Here, we integrate small-molecule high-throughput screening with a deep-learning-based virtual screening approach to uncover new antibacterial compounds. We screen ~2 million small molecules against a sensitized Escherichia coli strain, yielding thousands of hits. We use these data to train a deep learning model, GNEprop, to predict antibacterial activity, retrospectively validating robustness with respect to out-of-distribution generalization and activity cliff prediction. Virtual screening of over 1.4 billion synthetically accessible compounds identifies potential candidates, of which 82 exhibit antibacterial activity on the same strain, illustrating a 90-fold improved hit rate over the high-throughput screening experiment used for training. Many newly identified compounds exhibit high dissimilarity to known antibiotics, potency beyond the training bacterial strain and selectivity. Biological characterization identifies specific, validated targets, indicating promising avenues for further exploration in antibiotic discovery.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: G.S., S.T.R., Z.L., K.R.B., N.S., K.C., J-C.H., J.B., L.G., E.S., A.R, M.-W.T. and T.B. are employees of Genentech and shareholders of Roche. Y.B. is an advisor for Recursion Pharmaceuticals. A.R. is a cofounder and equity holder of Immunitas and, until July 31, 2020, was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. The other authors declare no competing interests.
References
LinkOut - more resources
Full Text Sources
